Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share

Nurix Therapeutics, Inc.

10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.
Gross proceeds of $175M; net proceeds estimated at ~$164M after underwriting discounts and expenses.
Proceeds to fund clinical development, R&D pipeline expansion, and working capital.
Underwriters granted 30-day option to purchase up to an additional 1.75M shares.
Offering expected to close on or about April 16, 2024, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated
Value: Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t
Effective: 2024-04-11

Exact text from the filing

On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).

View on SEC.gov

307 material agreements filed in the last 30 days. Browse all material agreements →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-094875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.